Vertex Pharma (VRTX) Tops Q2 EPS by 3c, raises guidance

Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.89, $0.03 better than the analyst estimate of $3.86. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.42 billion.

Guidance:
Company raises full year 2023 product revenue guidance to $9.7 to $9.8 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c